Compare RCMT & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | RCEL |
|---|---|---|
| Founded | 1971 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.6M | 306.5M |
| IPO Year | 1997 | 2018 |
| Metric | RCMT | RCEL |
|---|---|---|
| Price | $41.82 | $10.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $36.00 | $7.88 |
| AVG Volume (30 Days) | 77.4K | ★ 712.7K |
| Earning Date | 04-03-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.38 | 27.20 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $186,737,000.00 | $71,610,000.00 |
| Revenue This Year | $11.89 | $17.17 |
| Revenue Next Year | $12.46 | $49.82 |
| P/E Ratio | $34.14 | ★ N/A |
| Revenue Growth | 5.83 | ★ 11.45 |
| 52 Week Low | $17.26 | $3.22 |
| 52 Week High | $42.26 | $10.77 |
| Indicator | RCMT | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 77.79 | 77.22 |
| Support Level | $18.30 | $3.70 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.70 | 0.72 |
| MACD | 0.48 | 0.13 |
| Stochastic Oscillator | 94.20 | 92.92 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions, including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, and Europe.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.